The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients

M. Y. Choi; A. E. Clarke; Y. St Pierre; J. G. Hanly; M. B. Urowitz; J. Romero-Diaz; C. Gordon; S. C. Bae; S. Bernatsky; D. J. Wallace; J. T. Merrill; D. A. Isenberg; A. Rahman; E. M. Ginzler; M. Petri; I. N. Bruce; M. A. Dooley; P. Fortin; D. D. Gladman; J. Sanchez-Guerrero; K. Steinsson; R. Ramsey-Goldman; M. A. Khamashta; C. Aranow; G. S. Alarcón; S. Manzi; O. Nived; A. A. Zoma; R. F. Van Vollenhoven; M. Ramos-Casals; G. Ruiz-Irastorza; S. S. Lim; K. C. Kalunian; M. Inanc; D. L. Kamen; C. A. Peschken; S. Jacobsen; A. Askanase; J. Buyon; M. Mahler; Marvin J. Fritzler

doi:10.1177/0961203317692437

The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients

M. Y. Choi, A. E. Clarke, Y. St Pierre, J. G. Hanly, M. B. Urowitz, J. Romero-Diaz, C. Gordon, S. C. Bae, S. Bernatsky, D. J. Wallace, J. T. Merrill, D. A. Isenberg, A. Rahman, E. M. Ginzler, M. Petri, I. N. Bruce, M. A. Dooley, P. Fortin, D. D. Gladman, J. Sanchez-GuerreroK. Steinsson, R. Ramsey-Goldman, M. A. Khamashta, C. Aranow, G. S. Alarcón, S. Manzi, O. Nived, A. A. Zoma, R. F. Van Vollenhoven, M. Ramos-Casals, G. Ruiz-Irastorza, S. S. Lim, K. C. Kalunian, M. Inanc, D. L. Kamen, C. A. Peschken, S. Jacobsen, A. Askanase, J. Buyon, M. Mahler, Marvin J. Fritzler^*

^*Corresponding author for this work

Department of Clinical Medicine

30 Citations (Scopus)

Abstract

Autoantibodies to dense fine speckles 70 (DFS70) are purported to rule out the diagnosis of SLE when they occur in the absence of other SLE-related autoantibodies. This study is the first to report the prevalence of anti-DFS70 in an early, multinational inception SLE cohort and examine demographic, clinical, and autoantibody associations. Patients were enrolled in the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort within 15 months of diagnosis. The association between anti-DFS70 and multiple parameters in 1137 patients was assessed using univariate and multivariate logistic regression. The frequency of anti-DFS70 was 7.1% (95% CI: 5.7-8.8%), while only 1.1% (95% CI: 0.6-1.9%) were monospecific for anti-DFS70. In multivariate analysis, patients with musculoskeletal activity (Odds Ratio (OR) 1.24 [95% CI: 1.10, 1.41]) or with anti-β2 glycoprotein 1 (OR 2.17 [95% CI: 1.22, 3.87]) were more likely and patients with anti-dsDNA (OR 0.53 [95% CI: 0.31, 0.92]) or anti-SSB/La (OR 0.25 [95% CI: 0.08, 0.81]) were less likely to have anti-DFS70. In this study, the prevalence of anti-DFS70 was higher than the range previously published for adult SLE (7.1 versus 0-2.8%) and was associated with musculoskeletal activity and anti-β2 glycoprotein 1 autoantibodies. However, 'monospecific' anti-DFS70 autoantibodies were rare (1.1%) and therefore may be helpful to discriminate between ANA-positive healthy individuals and SLE.

Original language	English
Journal	Lupus
Volume	26
Issue number	10
Pages (from-to)	1051-1059
Number of pages	9
ISSN	0961-2033
DOIs	https://doi.org/10.1177/0961203317692437
Publication status	Published - Sept 2017

Keywords

Antinuclear antibodies
autoantibodies
DFS70
SLE

Access to Document

10.1177/0961203317692437

Cite this

Choi, M. Y., Clarke, A. E., St Pierre, Y., Hanly, J. G., Urowitz, M. B., Romero-Diaz, J., Gordon, C., Bae, S. C., Bernatsky, S., Wallace, D. J., Merrill, J. T., Isenberg, D. A., Rahman, A., Ginzler, E. M., Petri, M., Bruce, I. N., Dooley, M. A., Fortin, P., Gladman, D. D., ... Fritzler, M. J. (2017). The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus, 26(10), 1051-1059. https://doi.org/10.1177/0961203317692437

Choi, MY, Clarke, AE, St Pierre, Y, Hanly, JG, Urowitz, MB, Romero-Diaz, J, Gordon, C, Bae, SC, Bernatsky, S, Wallace, DJ, Merrill, JT, Isenberg, DA, Rahman, A, Ginzler, EM, Petri, M, Bruce, IN, Dooley, MA, Fortin, P, Gladman, DD, Sanchez-Guerrero, J, Steinsson, K, Ramsey-Goldman, R, Khamashta, MA, Aranow, C, Alarcón, GS, Manzi, S, Nived, O, Zoma, AA, Van Vollenhoven, RF, Ramos-Casals, M, Ruiz-Irastorza, G, Lim, SS, Kalunian, KC, Inanc, M, Kamen, DL, Peschken, CA, Jacobsen, S, Askanase, A, Buyon, J, Mahler, M & Fritzler, MJ 2017, 'The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients', Lupus, vol. 26, no. 10, pp. 1051-1059. https://doi.org/10.1177/0961203317692437

@article{69533b466cf54a0b8c233232ad8b6142,

title = "The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients",

abstract = "Autoantibodies to dense fine speckles 70 (DFS70) are purported to rule out the diagnosis of SLE when they occur in the absence of other SLE-related autoantibodies. This study is the first to report the prevalence of anti-DFS70 in an early, multinational inception SLE cohort and examine demographic, clinical, and autoantibody associations. Patients were enrolled in the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort within 15 months of diagnosis. The association between anti-DFS70 and multiple parameters in 1137 patients was assessed using univariate and multivariate logistic regression. The frequency of anti-DFS70 was 7.1% (95% CI: 5.7-8.8%), while only 1.1% (95% CI: 0.6-1.9%) were monospecific for anti-DFS70. In multivariate analysis, patients with musculoskeletal activity (Odds Ratio (OR) 1.24 [95% CI: 1.10, 1.41]) or with anti-β2 glycoprotein 1 (OR 2.17 [95% CI: 1.22, 3.87]) were more likely and patients with anti-dsDNA (OR 0.53 [95% CI: 0.31, 0.92]) or anti-SSB/La (OR 0.25 [95% CI: 0.08, 0.81]) were less likely to have anti-DFS70. In this study, the prevalence of anti-DFS70 was higher than the range previously published for adult SLE (7.1 versus 0-2.8%) and was associated with musculoskeletal activity and anti-β2 glycoprotein 1 autoantibodies. However, 'monospecific' anti-DFS70 autoantibodies were rare (1.1%) and therefore may be helpful to discriminate between ANA-positive healthy individuals and SLE.",

keywords = "Antinuclear antibodies, autoantibodies, DFS70, SLE",

author = "Choi, {M. Y.} and Clarke, {A. E.} and {St Pierre}, Y. and Hanly, {J. G.} and Urowitz, {M. B.} and J. Romero-Diaz and C. Gordon and Bae, {S. C.} and S. Bernatsky and Wallace, {D. J.} and Merrill, {J. T.} and Isenberg, {D. A.} and A. Rahman and Ginzler, {E. M.} and M. Petri and Bruce, {I. N.} and Dooley, {M. A.} and P. Fortin and Gladman, {D. D.} and J. Sanchez-Guerrero and K. Steinsson and R. Ramsey-Goldman and Khamashta, {M. A.} and C. Aranow and Alarc{\'o}n, {G. S.} and S. Manzi and O. Nived and Zoma, {A. A.} and {Van Vollenhoven}, {R. F.} and M. Ramos-Casals and G. Ruiz-Irastorza and Lim, {S. S.} and Kalunian, {K. C.} and M. Inanc and Kamen, {D. L.} and Peschken, {C. A.} and S. Jacobsen and A. Askanase and J. Buyon and M. Mahler and Fritzler, {Marvin J.}",

year = "2017",

month = sep,

doi = "10.1177/0961203317692437",

language = "English",

volume = "26",

pages = "1051--1059",

journal = "Lupus",

issn = "0961-2033",

publisher = "SAGE Publications",

number = "10",

}

TY - JOUR

T1 - The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients

AU - Choi, M. Y.

AU - Clarke, A. E.

AU - St Pierre, Y.

AU - Hanly, J. G.

AU - Urowitz, M. B.

AU - Romero-Diaz, J.

AU - Gordon, C.

AU - Bae, S. C.

AU - Bernatsky, S.

AU - Wallace, D. J.

AU - Merrill, J. T.

AU - Isenberg, D. A.

AU - Rahman, A.

AU - Ginzler, E. M.

AU - Petri, M.

AU - Bruce, I. N.

AU - Dooley, M. A.

AU - Fortin, P.

AU - Gladman, D. D.

AU - Sanchez-Guerrero, J.

AU - Steinsson, K.

AU - Ramsey-Goldman, R.

AU - Khamashta, M. A.

AU - Aranow, C.

AU - Alarcón, G. S.

AU - Manzi, S.

AU - Nived, O.

AU - Zoma, A. A.

AU - Van Vollenhoven, R. F.

AU - Ramos-Casals, M.

AU - Ruiz-Irastorza, G.

AU - Lim, S. S.

AU - Kalunian, K. C.

AU - Inanc, M.

AU - Kamen, D. L.

AU - Peschken, C. A.

AU - Jacobsen, S.

AU - Askanase, A.

AU - Buyon, J.

AU - Mahler, M.

AU - Fritzler, Marvin J.

PY - 2017/9

Y1 - 2017/9

N2 - Autoantibodies to dense fine speckles 70 (DFS70) are purported to rule out the diagnosis of SLE when they occur in the absence of other SLE-related autoantibodies. This study is the first to report the prevalence of anti-DFS70 in an early, multinational inception SLE cohort and examine demographic, clinical, and autoantibody associations. Patients were enrolled in the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort within 15 months of diagnosis. The association between anti-DFS70 and multiple parameters in 1137 patients was assessed using univariate and multivariate logistic regression. The frequency of anti-DFS70 was 7.1% (95% CI: 5.7-8.8%), while only 1.1% (95% CI: 0.6-1.9%) were monospecific for anti-DFS70. In multivariate analysis, patients with musculoskeletal activity (Odds Ratio (OR) 1.24 [95% CI: 1.10, 1.41]) or with anti-β2 glycoprotein 1 (OR 2.17 [95% CI: 1.22, 3.87]) were more likely and patients with anti-dsDNA (OR 0.53 [95% CI: 0.31, 0.92]) or anti-SSB/La (OR 0.25 [95% CI: 0.08, 0.81]) were less likely to have anti-DFS70. In this study, the prevalence of anti-DFS70 was higher than the range previously published for adult SLE (7.1 versus 0-2.8%) and was associated with musculoskeletal activity and anti-β2 glycoprotein 1 autoantibodies. However, 'monospecific' anti-DFS70 autoantibodies were rare (1.1%) and therefore may be helpful to discriminate between ANA-positive healthy individuals and SLE.

AB - Autoantibodies to dense fine speckles 70 (DFS70) are purported to rule out the diagnosis of SLE when they occur in the absence of other SLE-related autoantibodies. This study is the first to report the prevalence of anti-DFS70 in an early, multinational inception SLE cohort and examine demographic, clinical, and autoantibody associations. Patients were enrolled in the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort within 15 months of diagnosis. The association between anti-DFS70 and multiple parameters in 1137 patients was assessed using univariate and multivariate logistic regression. The frequency of anti-DFS70 was 7.1% (95% CI: 5.7-8.8%), while only 1.1% (95% CI: 0.6-1.9%) were monospecific for anti-DFS70. In multivariate analysis, patients with musculoskeletal activity (Odds Ratio (OR) 1.24 [95% CI: 1.10, 1.41]) or with anti-β2 glycoprotein 1 (OR 2.17 [95% CI: 1.22, 3.87]) were more likely and patients with anti-dsDNA (OR 0.53 [95% CI: 0.31, 0.92]) or anti-SSB/La (OR 0.25 [95% CI: 0.08, 0.81]) were less likely to have anti-DFS70. In this study, the prevalence of anti-DFS70 was higher than the range previously published for adult SLE (7.1 versus 0-2.8%) and was associated with musculoskeletal activity and anti-β2 glycoprotein 1 autoantibodies. However, 'monospecific' anti-DFS70 autoantibodies were rare (1.1%) and therefore may be helpful to discriminate between ANA-positive healthy individuals and SLE.

KW - Antinuclear antibodies

KW - autoantibodies

KW - DFS70

KW - SLE

U2 - 10.1177/0961203317692437

DO - 10.1177/0961203317692437

M3 - Journal article

C2 - 28420054

AN - SCOPUS:85025451913

SN - 0961-2033

VL - 26

SP - 1051

EP - 1059

JO - Lupus

JF - Lupus

IS - 10

ER -

The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients

Abstract

Keywords

Access to Document

Fingerprint

Cite this